95 related articles for article (PubMed ID: 27391928)
1. Somatostatin receptors in resected hepatocellular carcinoma: status and correlation with markers of poor prognosis.
Lequoy M; Desbois-Mouthon C; Wendum D; Gupta V; Blachon JL; Scatton O; Dumont S; Bonnemaire M; Schmidlin F; Rosmorduc O; Fartoux L
Histopathology; 2017 Feb; 70(3):492-498. PubMed ID: 27391928
[TBL] [Abstract][Full Text] [Related]
2. [Correlation of somatostatin receptor expression in human hepatocellular carcinoma tissue to serum alpha-fetoprotein concentration].
Xie YM; Yan LN; Wei B; Guo MM; Tang CW
Ai Zheng; 2007 Jul; 26(7):688-92. PubMed ID: 17626741
[TBL] [Abstract][Full Text] [Related]
3. Somatostatin and CXCR4 chemokine receptor expression in hepatocellular and cholangiocellular carcinomas: tumor capillaries as promising targets.
Kaemmerer D; Schindler R; Mußbach F; Dahmen U; Altendorf-Hofmann A; Dirsch O; Sänger J; Schulz S; Lupp A
BMC Cancer; 2017 Dec; 17(1):896. PubMed ID: 29282035
[TBL] [Abstract][Full Text] [Related]
4. Differential expression of somatostatin receptor subtypes in hepatocellular carcinomas.
Bläker M; Schmitz M; Gocht A; Burghardt S; Schulz M; Bröring DC; Pace A; Greten H; De Weerth A
J Hepatol; 2004 Jul; 41(1):112-8. PubMed ID: 15246216
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor 1 (SSTR1) and somatostatin receptor 5 (SSTR5)expression in hepatocellular carcinoma.
Koc EU; Ozgur T; Yerci O; Gurel S
Hepatogastroenterology; 2013 Oct; 60(127):1693-7. PubMed ID: 24634938
[TBL] [Abstract][Full Text] [Related]
6. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1--5 and correlation with receptor protein expression and tumor pathology.
Kumar U; Grigorakis SI; Watt HL; Sasi R; Snell L; Watson P; Chaudhari S
Breast Cancer Res Treat; 2005 Jul; 92(2):175-86. PubMed ID: 15986128
[TBL] [Abstract][Full Text] [Related]
7. Characterization of somatostatin receptor 2 and 5 expression in operable hepatocellular carcinomas.
Li S; Liu Y; Shen Z
Hepatogastroenterology; 2012 Oct; 59(119):2054-8. PubMed ID: 22640914
[TBL] [Abstract][Full Text] [Related]
8. Neuron-glial antigen 2 overexpression in hepatocellular carcinoma predicts poor prognosis.
Lu LL; Sun J; Lai JJ; Jiang Y; Bai LH; Zhang LD
World J Gastroenterol; 2015 Jun; 21(21):6649-59. PubMed ID: 26074703
[TBL] [Abstract][Full Text] [Related]
9. Somatostatin and dopamine receptor expression in neuroendocrine neoplasms: correlation of immunohistochemical findings with somatostatin receptor scintigraphy visual scores.
Diakatou E; Alexandraki KI; Tsolakis AV; Kontogeorgos G; Chatzellis E; Leonti A; Kaltsas GA
Clin Endocrinol (Oxf); 2015 Sep; 83(3):420-8. PubMed ID: 25808161
[TBL] [Abstract][Full Text] [Related]
10. Decreased expression of liver-type fatty acid-binding protein is associated with poor prognosis in hepatocellular carcinoma.
Wang B; Tao X; Huang CZ; Liu JF; Ye YB; Huang AM
Hepatogastroenterology; 2014; 61(133):1321-6. PubMed ID: 25436304
[TBL] [Abstract][Full Text] [Related]
11. MicroRNA-7 downregulates the oncogene VDAC1 to influence hepatocellular carcinoma proliferation and metastasis.
Wang F; Qiang Y; Zhu L; Jiang Y; Wang Y; Shao X; Yin L; Chen J; Chen Z
Tumour Biol; 2016 Aug; 37(8):10235-46. PubMed ID: 26831666
[TBL] [Abstract][Full Text] [Related]
12. Serine/arginine rich splicing factor 2 expression and clinic pathological features indicating a prognostic factor in human hepatocellular carcinoma patients.
Wang P; Guo L; Li K; Ning S; Shi W; Liu Z; Chen Y
Cancer Biomark; 2018 Feb; 21(3):681-687. PubMed ID: 29278882
[TBL] [Abstract][Full Text] [Related]
13. Down-regulation of the tumour suppressor κ-opioid receptor predicts poor prognosis in hepatocellular carcinoma patients.
Chen D; Chen Y; Yan Y; Pan J; Xing W; Li Q; Zeng W
BMC Cancer; 2017 Aug; 17(1):553. PubMed ID: 28821282
[TBL] [Abstract][Full Text] [Related]
14. Expression of somatostatin receptors (SSTR1-SSTR5) in meningiomas and its clinicopathological significance.
Silva CB; Ongaratti BR; Trott G; Haag T; Ferreira NP; Leães CG; Pereira-Lima JF; Oliveira Mda C
Int J Clin Exp Pathol; 2015; 8(10):13185-92. PubMed ID: 26722517
[TBL] [Abstract][Full Text] [Related]
15. Up-regulation of AKAP13 and MAGT1 on cytoplasmic membrane in progressive hepatocellular carcinoma: a novel target for prognosis.
Molee P; Adisakwattana P; Reamtong O; Petmitr S; Sricharunrat T; Suwandittakul N; Chaisri U
Int J Clin Exp Pathol; 2015; 8(9):9796-811. PubMed ID: 26617690
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of KIF23 variant 1 expression and relevance as a novel prognostic factor in patients with hepatocellular carcinoma.
Sun X; Jin Z; Song X; Wang J; Li Y; Qian X; zhang Y; Yin Y
BMC Cancer; 2015 Dec; 15():961. PubMed ID: 26674738
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of betaine homocysteine methyltransferase (BHMT) in hepatocellular carcinoma associates with poor prognosis.
Jin B; Gong Z; Yang N; Huang Z; Zeng S; Chen H; Hu S; Pan G
Tumour Biol; 2016 May; 37(5):5911-7. PubMed ID: 26592251
[TBL] [Abstract][Full Text] [Related]
18. Dopamine 2 and somatostatin 1-5 receptors coexpression in clinically non-functioning pituitary adenomas.
Gabalec F; Drastikova M; Cesak T; Netuka D; Masopust V; Machac J; Marek J; Cap J; Beranek M
Physiol Res; 2015; 64(3):369-77. PubMed ID: 25536318
[TBL] [Abstract][Full Text] [Related]
19. Glutamine synthetase as an early marker for hepatocellular carcinoma based on proteomic analysis of resected small hepatocellular carcinomas.
Long J; Lang ZW; Wang HG; Wang TL; Wang BE; Liu SQ
Hepatobiliary Pancreat Dis Int; 2010 Jun; 9(3):296-305. PubMed ID: 20525558
[TBL] [Abstract][Full Text] [Related]
20. Hepatocellular carcinomas expressing 'stemness'-related markers: clinicopathological characteristics.
Kim H; Park YN
Dig Dis; 2014; 32(6):778-85. PubMed ID: 25376296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
